Rehovot, Israel
June 1st, 2011

Evogene Ltd. (TASE: EVGN) announced today that it has received $16.6 million from the exercise of the company's series 2 warrants. The warrants, which expired May 31, 2011, were issued in June 2007 as part of the company’s initial public offering on the Tel Aviv Stock Exchange and as part of an investment agreement signed with AquAgro Fund L.P on April 2008.

Ofer Haviv, Evogene's president and CEO, stated: "We greatly appreciate these additional votes of confidence from our existing and new investors, as represented by these further investments in our Company, resulting in the exercise of 99.9% of the outstanding series 2 warrants," Mr. Haviv continued. “Evogene has maintained a rapid pace of growth and development since our IPO and we expect to continue this progress in the coming years. This includes continued progress in our current and future collaborations, as well as further expansion of our core technologies and its commercial applications."

As of March 31, 2011, Evogene had $50.1 million in cash, cash equivalents, cash deposits and short-term marketable securities. This includes $3.6 million of the $16.6 million that has been received from the exercise of series 2 warrants; the remaining $13 million were received after March 31, 2001.

Website: http://www.evogene.com

Published: June 1, 2011